A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.

Leroy I, d'Acremont M, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P

Fertility and sterility1 Sept 1994Cited by 52 (Europe PMC)

PMID8062939DOI10.1016/s0015-0282(16)56932-5PepBankPUB-08062939

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix interrupted the LH surge in every case.
In plain wordsIn normal women, cetrorelix interrupted the LH surge in every case.
Peptide
Cetrorelix
Outcome
DecreaseLH surge interruption
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg (group 1) or 3 mg (group 2) · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
The LH surge was interrupted in every case.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293907
02HumanNon-randomized trialSafety outcome
In normal women, very slight, transient injection-site erythema was observed after cetrorelix.
In plain wordsIn normal women, very slight, transient injection-site redness occurred after cetrorelix.
Peptide
Cetrorelix
Outcome
Not applicableInjection-site erythema
Study
n = 10
Outcome group
Adverse events · Skin and wound
Studied dose
5 mg (group 1) or 3 mg (group 2) · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
No adverse effects were observed, except for very slight and transient erythema and pruritus at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293912
03HumanNon-randomized trialSafety outcome
In normal women, very slight, transient injection-site pruritus was observed after cetrorelix.
In plain wordsIn normal women, very slight, transient injection-site itching occurred after cetrorelix.
Peptide
Cetrorelix
Outcome
Not applicableInjection-site pruritus
Study
n = 10
Outcome group
Adverse events · Skin and wound
Studied dose
5 mg (group 1) or 3 mg (group 2) · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
No adverse effects were observed, except for very slight and transient erythema and pruritus at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293913
04HumanNon-randomized trialSafety outcome
In normal women, no other adverse effects were observed after cetrorelix beyond local erythema and pruritus.
In plain wordsIn normal women, no other adverse effects occurred after cetrorelix beyond local redness and itching.
Peptide
Cetrorelix
Outcome
Not applicableOther adverse effects
Study
n = 10
Outcome group
Adverse events · Whole body
Studied dose
5 mg (group 1) or 3 mg (group 2) · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
No adverse effects were observed, except for very slight and transient erythema and pruritus at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293914
05HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 5 mg reduced LH by 56% +/- 19%, reaching its nadir at 24 hours.
In plain wordsIn normal women, cetrorelix 5 mg reduced LH by 56% +/- 19% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseLH decrease
Study
n = 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
LH decrease
56%
group 1 (5 mg), mean
LH decrease SD
19%
group 1 (5 mg), SD
time to nadir after administration
24 hours
group 1 (5 mg)
Source sentences
Summary
Plasma LH and FSH decreased by 56% +/- 19% and 29.5% +/- 16% (mean +/- SD), respectively, reaching the nadir 24 hours after Cetrorelix administration.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293901
06HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 5 mg reduced FSH by 29.5% +/- 16%, reaching its nadir at 24 hours.
In plain wordsIn normal women, cetrorelix 5 mg reduced FSH by 29.5% +/- 16% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseFSH decrease
Study
n = 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
FSH decrease
29.5%
group 1 (5 mg), mean
FSH decrease SD
16%
group 1 (5 mg), SD
time to nadir after administration
24 hours
group 1 (5 mg)
Source sentences
Summary
Plasma LH and FSH decreased by 56% +/- 19% and 29.5% +/- 16% (mean +/- SD), respectively, reaching the nadir 24 hours after Cetrorelix administration.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293902
07HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 5 mg reduced estradiol by 85% +/- 17%, reaching its nadir at 48 hours.
In plain wordsIn normal women, cetrorelix 5 mg reduced estradiol by 85% +/- 17% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol decrease
Study
n = 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
Estradiol decrease
85%
group 1 (5 mg), mean
Estradiol decrease SD
17%
group 1 (5 mg), SD
time to nadir after administration
48 hours
group 1 (5 mg)
Source sentences
Summary
Estradiol decreased by 85% +/- 17%, reaching the nadir 48 hours after antagonist injection.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293903
08HumanNon-randomized trialEfficacy outcome
In six of seven women given cetrorelix 5 mg, the LH surge occurred 6 to 17 days after injection.
In plain wordsIn six of seven women given cetrorelix 5 mg, the LH surge occurred 6 to 17 days after injection.
Peptide
Cetrorelix
Outcome
IncreaseLH surge delay
Study
n = 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
subjects with delayed LH surge
6 subjects
group 1 (5 mg), of 7 subjects
surge timing after injection
6 to 17 days
group 1 (5 mg)
Source sentences
Summary
In six of seven subjects from group 1, the LH surge was delayed, occurring 6 to 17 days after the antagonist injection.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293908
09HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 3 mg reduced LH by 66% +/- 18%, reaching its nadir at 24 hours.
In plain wordsIn normal women, cetrorelix 3 mg reduced LH by 66% +/- 18% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseLH decrease
Study
n = 3
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg · subcutaneous · single doseAs given in this study (human).
Measurements
LH decrease
66%
group 2 (3 mg), mean
LH decrease SD
18%
group 2 (3 mg), SD
time to nadir after administration
24 hours
group 2 (3 mg)
Source sentences
Summary
Plasma LH and FSH decreased by 66% +/- 18% and 32% +/- 6%, respectively, reaching a nadir 24 hours after Cetrorelix administration.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293904
10HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 3 mg reduced FSH by 32% +/- 6%, reaching its nadir at 24 hours.
In plain wordsIn normal women, cetrorelix 3 mg reduced FSH by 32% +/- 6% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseFSH decrease
Study
n = 3
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg · subcutaneous · single doseAs given in this study (human).
Measurements
FSH decrease
32%
group 2 (3 mg), mean
FSH decrease SD
6%
group 2 (3 mg), SD
time to nadir after administration
24 hours
group 2 (3 mg)
Source sentences
Summary
Plasma LH and FSH decreased by 66% +/- 18% and 32% +/- 6%, respectively, reaching a nadir 24 hours after Cetrorelix administration.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293905
11HumanNon-randomized trialEfficacy outcome
In normal women, cetrorelix 3 mg reduced estradiol by 81% +/- 9%, reaching its nadir at 24 to 48 hours.
In plain wordsIn normal women, cetrorelix 3 mg reduced estradiol by 81% +/- 9% from baseline.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol decrease
Study
n = 3
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg · subcutaneous · single doseAs given in this study (human).
Measurements
Estradiol decrease
81%
group 2 (3 mg), mean
Estradiol decrease SD
9%
group 2 (3 mg), SD
time to nadir after administration
24 to 48 hours
group 2 (3 mg)
Source sentences
Summary
Estradiol decreased by 81% +/- 9%, reaching the nadir 24 to 48 hours after antagonist administration.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293906
12HumanNon-randomized trialEfficacy outcome
In three of three women given cetrorelix 3 mg, the LH surge occurred 6 to 9 days after injection.
In plain wordsIn three of three women given cetrorelix 3 mg, the LH surge occurred 6 to 9 days after injection.
Peptide
Cetrorelix
Outcome
IncreaseLH surge delay
Study
n = 3
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg · subcutaneous · single doseAs given in this study (human).
Measurements
subjects with delayed LH surge
3 subjects
group 2 (3 mg), of 3 subjects
surge timing after injection
6 to 9 days
group 2 (3 mg)
Source sentences
Summary
In group 2, in three of three subjects, the LH surge was delayed, occurring 6 to 9 days after the antagonist injection.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293911
13HumanNon-randomized trialEfficacy outcome
In one woman given cetrorelix at LH surge onset, LH fell immediately by 54% from 13 IU/L.
In plain wordsIn one woman given cetrorelix at surge onset, LH fell immediately by 54% from 13 IU/L.
Peptide
Cetrorelix
Outcome
DecreaseLH decrease during ongoing surge
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
LH at start of surge
13 IU/L
single woman
LH fall
54%
single woman, immediately after injection
Source sentences
Summary
In the remaining woman, Cetrorelix was administered at the beginning of the LH surge (LH = 13 IU/L): the LH level fell immediately by 54%, and the surge was postponed by 3 days.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293909
14HumanNon-randomized trialEfficacy outcome
In one woman given cetrorelix at LH surge onset, the surge was postponed by 3 days.
In plain wordsIn one woman given cetrorelix at LH surge onset, the surge was postponed by 3 days.
Peptide
Cetrorelix
Outcome
IncreaseOngoing LH surge postponement
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5 mg · subcutaneous · single doseAs given in this study (human).
Measurements
surge postponement
3 days
single woman given cetrorelix at surge onset
Source sentences
Summary
In the remaining woman, Cetrorelix was administered at the beginning of the LH surge (LH = 13 IU/L): the LH level fell immediately by 54%, and the surge was postponed by 3 days.
2 context sentences(design, population, supporting numbers)
Summary · context
A single 5-mg (group 1, n = 7) or 3-mg (group 2, n = 3) dose SC of Cetrorelix was administered during the late follicular phase, on the day of the cycle when plasma E2 exceeded 150 pg/mL (550 pmol/L).
Summary · context
Ten normal women with regular ovulatory menstrual cycles.
Report a problemFND-0806293910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingNot applicableNCT06378268

PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)

Mỹ Đức Hospitaln = 62624 Apr 2024 to est. 30 Sept 2026

Progestins Primed Ovarian Stimulation

Trial page ClinicalTrials.govUpdated 20 Mar 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.